Adocia

Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the
field of metabolic diseases, primarily diabetes and obesity.
The company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The
BioChaperone® technology for the development of new generation insulins and products combining insulins with
other classes of hormones; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective
biomaterial for cell transplantation, with a first application in pancreatic cells transplantation; 4) AdoGel®, a long-acting drug delivery platform.
Adocia holds more than 25 patent families. Based in Lyon, the company has about 100 employees. Adocia is listed
on the regulated market of Euronext Paris.